Forte Biosciences (FBRX) stock soared on Monday after the clinical-stage biopharmaceutical company announced results from a Phase 1b trial of FB102. This is the company’s lead program designed to treat celiac disease. It included evaluations of assessed morphologic and inflammatory endpoints, as well as gluten challenge (GC)-induced symptoms.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Forte Biosciences’ Phase 1b study achieved statistical significance, including a change in density of CD3-positive T cells. It also resulted in a Vh:Cd ratio change and a 42% benefit for patients during the GC. The company also announced that it has initiated the Phase 2 stage of this study, with topline results expected in the first half of 2026.
FBRX stock was up 23.53% on Monday, following a 17.8% rally on Friday. The company’s shares were down 35.45% year-to-date but have rallied 19.67% over the past 12 months.
Is Forte Biosciences Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Forte Biosciences is Strong Buy, based on three Buy ratings over the past three months. With that comes an average FBRX stock price target of $44.50, representing a potential 203.55% upside for the shares.
